Current and future treatment options for gonorrhoea

Sexually Transmitted Infections

Volumn 89, Issue SUPPL. 4, 2013, Pages

  Ison, Catherine A ^a   Deal, Carolyn ^b   Unemo, Magnus ^c  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CEFTRIAXONE; CEPHALOSPORIN; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; DOXYCYCLINE; PENICILLIN DERIVATIVE;

ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; DISEASE PREDISPOSITION; DRUG USE; GONORRHEA; HUMAN; MEN WHO HAVE SEX WITH MEN; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; POINT OF CARE TESTING; PRACTICE GUIDELINE; PRIORITY JOURNAL; TREATMENT FAILURE;

ANTIMICROBIAL RESISTANCE; ANTIMICROBIAL TREATMENT; CEFIXIME; CEFTRIAXONE; GONORRHOEA; NEISSERIA GONORRHOEAE;

ADMINISTRATION, INTRAVENOUS; ANTI-BACTERIAL AGENTS; BACTERIAL VACCINES; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; GONORRHEA; HUMANS; NEISSERIA GONORRHOEAE;

EID: 84891847324     PISSN: 13684973     EISSN: 14723263     Source Type: Journal    
DOI: 10.1136/sextrans-2012-050913     Document Type: Article

References (60)

1. World Health Organization. Guidelines for the management of sexually transmitted diseases. World Health Organization, 2003. ISBN: 92 4 154626 3. http://www.who. int/hiv/pub/sti/en/STIGuidelines2003.pdf (accessed 13 Mar 2013).
2. Cole MJ, Chisholm SA, Hoffmann S, et al. European surveillance of antimicrobial resistance in Neisseria gonorrhoeae. Sex Transm Infect 2010;86:427-32.
3. Gonococcal Resistance to Antimicrobials Surveillance Programme in England and Wales (GRASP): Report of 2009 data. Health Protection Report 2010;4.
4. Eastick K. Gonococcal antibiotic surveillance in Scotland (GASS): Prevalence, patterns and trends in 2009. HPS Weekly Report 2010;25:339-42.
5. Gorwitz RJ, Nakashima AK, Moran JS, et al. Sentinel surveillance for antimicrobial resistance in Neisseria gonorrhoeae-United States, 1988-1991. The Gonococcal Isolate Surveillance Project Study Group. MMWR CDC Surveill Summ 1993;42:29-39.
6. Samaan G, Roche PW, Greig JE, et al. Evaluation of the Australian Gonococcal Surveillance Programme. Commun Dis Intell Q Rep 2005;29:143-9.
7. Tapsall JW. Surveillance of antibiotic resistance in Neisseria gonorrhoeae in the WHO Western Pacific Region, 1998. The WHO Western Pacific Gonococcal Antimicrobial Surveillance Programme. Commun Dis Intell 2000;24:1-4.
8. Dillon JA. Sustainable antimicrobial surveillance programs essential for controlling Neisseria gonorrhoeae superbug. Sex Transm Dis 2011;38:899-901.
9. Centre for Disease Control and Prevention (CDC). Antibiotic-resistant strains of Neisseria gonorrhoeae: Policy guidelines for detection, management and control. MMWR 1987;36(Suppl 5S):1S-18S.
10. Roy K, Wang SA, Meltzer MI. Optimizing treatment of antimicrobial- resistant Neisseria gonorrhoeae. Emerg Infect Dis 2005;11:1265-73. (Pubitemid 41045336)
11. Centers for Disease Control and Prevention (CDC). Update to CDC's sexually transmitted diseases treatment guidelines, 2010: Oral cephalosporins no longer a recommended treatment for gonococcal infections. MMWR Morb Mortal Wkly Rep 2012;61:590-4.
12. Bignell C, Fitzgerald M; Guideline Development Group. UK national guideline for the management of gonorrhoea in adults, 2011. Int J STD AIDS 2011; 22:541-7.
13. Bignell C, Unemo M, on behalf of the European STI Guidelines Editorial Board. 2012 European guideline on the diagnosis and treatment of gonorrhoea in adults. Int J STD AIDS 2013;24:85-92.
14. Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2010. MMWR 2010;59(No. RR-12):49-55.
15. GRASP Steering Group. The gonococcal resistance to antimicrobials programme (GRASP) year 2010 report. London: Health Protection Agency, 2011. http://www. hpa.org.uk/webc/HPAwebFile/HPAweb-C/1316016752917 (accessed 4 May 2013).
16. Brown LB, Krysiak R, Kamanga G, et al. Neisseria gonorrhoeae antimicrobial susceptibility in Lilongwe, Malawi, 2007. Sex Transm Dis 2010;37:169-72.
17. Chisholm SA, Quaye N, Cole MJ, et al. An evaluation of gentamicin susceptibility of Neisseria gonorrhoeae isolates in Europe. J Antimicrob Chemother 2011;66:592-5.
18. Lewis DA. The gonococcus fights back: Is this time a knock out? Sex Transm Infect 2010;86:415-21.
19. World Health Organization (WHO), Department of Reproductive Health and Research. Global action plan to control the spread and impact of antimicrobial resistance in Neisseria gonorrhoeae. Geneva: WHO, 2012:1-36. http://www.who. int/reproductivehealth/publications/rtis/9789241503501 (accessed 4 May 2013).
20. Centers for Disease Control and Prevention (CDC). Cephalosporin-resistant Neisseria gonorrhoeae public health response plan. 2012:1-43. http://www.cdc.gov/std/gonorrhea/default.htm (accessed 4 May 2013).
21. European Centre for Disease Prevention and Control (ECDC). Response plan to control and manage the threat of multidrug-resistant gonorrhoea in Europe. Stockholm: ECDC, 2012:1-23. http://www.ecdc.europa.eu/en/publications/ Publications/1206-ECDC-MDR-gonorrhoea-response-plan.pdf (accessed 4 May 2013).
22. Tapsall JW, Ndowa F, Lewis DA, et al. Meeting the public health challenge of multidrug-and extensively drug-resistant Neisseria gonorrhoeae. Expert Rev Anti Infect Ther 2009;7:821-34.
23. Chisholm SA, Mouton JW, Lewis DA, et al. Cephalosporin MIC creep among gonococci: Time for a pharmacodynamic rethink? J Antimicrob Chemother 2010;65:2141-8.
24. Unemo M, Shipitsyna E, Domeika M; on behalf of the Eastern European Sexual and Reproductive Health (EE SRH) Network Antimicrobial Resistance Group. Recommended antimicrobial treatment of uncomplicated gonorrhoea in 2009 in 11 East European countries: Implementation of a Neisseria gonorrhoeae antimicrobial susceptibility programme in this region is crucial. Sex Transm Infect 2010;86:442-4.
25. Tapsall JW. Implications of current recommendations for third-generation cephalosporin use in the WHO Western Pacific Region following the emergence of multiresistant gonococci. Sex Transm Infect 2009;85:256-8.
26. Japanese Society of Sexually Transmitted Infection. Gonococcal infection. Sexually transmitted infections, diagnosis and treatment guidelines 2011. Jpn J Sex Transm Dis 2011;22(Suppl 1):52-9. (Japanese).
27. Muratani T, Inatomi H, Ando Y, et al. Single dose 1 g ceftriaxone for urogenital and pharyngeal infection caused by Neisseria gonorrhoeae. Int J Urol 2008;15:837-42.
28. Jaffe HW, Schroeter AL, Reynold GH, et al. Pharmacokinetic determinants of penicillin cure of gonococcal urethritis. Antimicrob Agents Chemother 1979;15:587-91. (Pubitemid 9152440)
29. European Centre for Disease Prevention and Control (ECDC). Gonococcal antimicrobial susceptibility surveillance in Europe 2010. Stockholm: ECDC, 2012. http://ecdc.europa.eu/en/publications/Publications/1206-Gonococcal-AMR.pdf (accessed 4 May 2013).
30. Unemo M, Golparian D, Hestner A. Ceftriaxone treatment failure of pharyngeal gonorrhoea verified by international recommendations, Sweden, July 2010. Euro Surveill 2011;16:p11=19792.
31. Ohnishi M, Golparian D, Shimuta K, et al. Is Neisseria gonorrhoeae initiating a future era of untreatable gonorrhea? Detailed characterization of the first strain with high-level resistance to ceftriaxone. Antimicrob Agents Chemother 2011;55:3538-45.
32. Unemo M, Golparian D, Nicholas R, et al. High-level cefixime-and ceftriaxone-resistant N. gonorrhoeae in France: Novel penA mosaic allele in a successful international clone causes treatment failure. Antimicrob Agents Chemother 2012;56:1273-80.
33. Unemo M, Golparian D, Syversen G, et al. Two cases of verified clinical failures using internationally recommended first-line cefixime for gonorrhoea treatment, Norway, 2010. Euro Surveill 2010;15:pii=19721.
34. Ison CA, Hussey J, Sankar KN, et al. Gonorrhoea treatment failures to cefixime and azithromycin in England, 2010. Euro Surveill 2011;16:pii=19833.
35. Unemo M, Golparian D, Stary A, et al. First Neisseria gonorrhoeae strain with resistance to cefixime causing gonorrhoea treatment failure in Austria. Euro Surveill 2011;16:pii=19998.
36. Unemo M, Golparian D, Potočnik M, et al. Treatment failure of pharyngeal gonorrhoea with internationally recommended first-line ceftriaxone verified in Slovenia, September 2011. Euro Surveill 2012;17:pii=20200.
37. Lewis DA, Sriruttan C, Müller EE, et al. Phenotypic and genetic characterization of the first two cases of extended-spectrum-cephalosporin- resistant Neisseria gonorrhoeae infection in South Africa and association with cefixime treatment failure. J Antimicrob Chemother 2013;68:1267-70.
38. Allen VG, Mitterni L, Seah C, et al. Neisseria gonorrhoeae treatment failure and susceptibility to cefixime in Toronto, Canada. JAMA 2013;309:163-70.
39. Furuya R, Nakayama H, Kanayama A, et al. In vitro synergistic effects of double combinations of beta-lactams and azithromycin against clinical isolates of Neisseria gonorrhoeae. J Infect Chemother 2006;12:172-6. (Pubitemid 44327183)
40. Sathia L, Ellis B, Phillip S, et al. Pharyngeal gonorrhoea-is dual therapy the way forward? Int J STD AIDS 2007;18:647-8. (Pubitemid 351738928)
41. Barbee LA, Kerani RP, Dombrowski JC, et al. A retrospective comparative study of 2-drug oral and intramuscular cephalosporin treatment regimens for pharyngeal gonorrhea. Clin Infect Dis 2013;56:1539-45.
42. Pereira R, Cole MJ, Ison CA. Combination therapy for gonorrhoea: In vitro synergy testing. J Antimicrob Chemother 2013;68:640-3.
43. Palmer HM, Young H, Winter A, et al. Emergence and spread of azithromycin-resistant Neisseria gonorrhoeae in Scotland. J Antimicrob Chemother 2008;62:490-4.
44. Chisholm SA, Dave J, Ison CA. High-level azithromycin resistance occurs in Neisseria gonorrhoeae as a result of a single point mutation in the 23S rRNA genes. Antimicrob Agents Chemother 2010;54:3812-16.
45. Starnino S, Stefanelli P; Neisseria gonorrhoeae Italian Study Group I. Azithromycin-resistant Neisseria gonorrhoeae strains recently isolated in Italy. J Antimicrob Chemother 2009;63:1200-4.
46. Galarza PG, Abad R, Canigia LF, et al. New mutation in 23S rRNA gene associated with high level of azithromycin resistance in Neisseria gonorrhoeae. Antimicrob Agents Chemother 2010;54:1652-3.
47. Katz AR, Komeya AY, Soge OO, et al. Neisseria gonorrhoeae with high-level resistance to azithromycin: Case report of the first isolate identified in the United States. Clin Infect Dis 2012;54:841-3.
48. Kirkcaldy RD. Treatment of gonorrhoea in an era of emerging cephalosporin resistance and results of a randomized trial of new potential treatment options, STI & AIDS World Congress 2013. Vienna, Austria, 14-17 July 2013. Abstract SO8.1.
49. Biedenbach DJ, Turner LL, Jones RN, et al. Activity of JNJ-Q2, a novel fluoroquinolone, tested against Neisseria gonorrhoeae, including ciprofloxacin-resistant strains. Diagn Microbiol Infect Dis 2012;74:204-6.
50. Golparian D, Fernandes P, Ohnishi M, et al. In vitro activity of the new fluoroketolide solithromycin (CEM-101) against a large collection of clinical Neisseria gonorrhoeae isolates and international reference strains including those with various high-level antimicrobial resistance-potential treatment option for gonorrhea? Antimicrob Agents Chemother 2012;56:2739-42.
51. Hook E III, Oldach D, Jamieson B, et al. A phase 2 study to evaluate the efficacy and safety of single dose solithromycin (CEM-101) for the treatment of patients with uncomplicated urogenital gonorrhoea. European Congress of Clinical Microbiology and Infectious Disease Berlin 2013 Abstract O274.
52. Novak R. Are pleuromutilin antibiotics finally fit for human use? Ann NY Acad Sci 2011;1241:71-81.
53. Bradbury BJ, Pucci MJ. Recent advances in bacterial topoisomerase inhibitors. Curr Opin Pharmacol 2008;8:574-81.
54. Goire N, Lahra M, Ohnishi M, et al. Polymerase chain reaction-based screening for the ceftriaxone-resistant Neisseria gonorrhoeae F89 strain. Euro Surveill 2013;18: Pii=20444.
55. Goire N, Sloots TP, Nissen MD, et al. Protocol for the molecular detection of antibiotic resistance mechanisms in Neisseria gonorrhoeae. Methods Mol Biol 2012;903:319-28.
56. Unemo M, Nicholas RA. Emergence of multidrug-resistant, extensively drug-resistant and untreatable gonorrhea. Future Microbiol 2012;7:1401-22.
57. Zhu W, Chen CJ, Thomas CE, et al. Vaccines for gonorrhea: Can we rise to the challenge? Front Microbiol 2011;2:124.
58. Hobbs MM, Sparling PF, Cohen MS, et al. Experimental gonococcal infection in male volunteers: Cumulative experience with Neisseria gonorrhoeae strains FA1090 and MS11mkc. Front Microbiol 2011;2:123.
59. Guiliani MM, Adu-Bobie J, Comanducci M, et al. A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci USA 2006;103:10834-39. (Pubitemid 44148381)
60. Borges O, Lebre F, Bento D, et al. Mucosal vaccines: Recent progress in understanding the natural barriers. Pharm Res 2010;27:211-23.